Results 171 to 180 of about 663,256 (217)

Tertiary Lymphoid Structures Are Associated with Progression-Free Survival of Peripheral Neuroblastic Tumor Patients. [PDF]

Cancers (Basel)
Rothe R, Golle T, Hachkar B, Hörz T, Pablik J, Rupp L, Dietsche I, Kruppa C, Fitze G, Schmitz M, Haase M, Wehner R.   +11 more
europepmc   +1 more source

Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study. [PDF]

Oncol Ther
Boré P, Geier M, Campion L, Raoul JL, Doucet L, Hiret S, Bigot F, Bocquet F, Mezquita L, Gorria T, Raimbourg J.   +10 more
europepmc   +1 more source

Osimertinib prolongs progression‐free lung cancer survival after chemotherapy

CA: A Cancer Journal for Clinicians
openaire   +2 more sources

Comparative study on the predictive value of TyG, TyG-BMI, and TG/HDL-C for progression-free survival in patients with locally advanced nasopharyngeal carcinoma. [PDF]

Front Nutr
Xiao Z, Liang Z, Chen W, Huang H, Qu S.
europepmc   +1 more source

Relationship between HuR and patients’ outcome was estimated with pan-cancer disease specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) analysis.

Jian Peng (117876), Jichuan Quan (11406050), Xiaoru Wang (345528)   +2 more
openalex   +1 more source

Prognostic Value of Pre-Treatment Diffusion Kurtosis Imaging for Progression-Free Survival Prediction in Advanced Nasopharyngeal Carcinoma. [PDF]

Cancer Med
Ren W, Zheng X, Wu S, Wu C, Zheng D.
europepmc   +1 more source

The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis. [PDF]

Cancers (Basel)
Zuellig JA, Adam R, Udry F, Tibau A, Šeruga B, Ocaña A, Amir E, Templeton AJ.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Concordance index: Surrogacy of progression-free survival for overall survival

Contemporary Clinical Trials, 2021
In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire   +2 more sources